a public good project by the
Synthesis
Company
of California

© 2026

Weiming You | doi.page

0 works0 citations0 h-index

Weiming You

First Affiliated Hospital of Xi'an Jiaotong University(CN)Second Affiliated Hospital of Xi'an Jiaotong University(CN)

Publications by Year

Research Areas

Nanoplatforms for cancer theranostics, Radiomics and Machine Learning in Medical Imaging, Peptidase Inhibition and Analysis, RNA Interference and Gene Delivery, Chemical Synthesis and Analysis

Most-Cited Works

→ Nanoparticle delivery of miR-21-3p sensitizes melanoma to anti-PD-1 immunotherapy by promoting ferroptosis(2022)117 cited
→ A nano-predator of pathological MDMX construct by clearable supramolecular gold(I)-thiol-peptide complexes achieves safe and potent anti-tumor activity(2021)96 cited
→ Self‐Assembly of Therapeutic Peptide into Stimuli‐Responsive Clustered Nanohybrids for Cancer‐Targeted Therapy(2019)82 cited
→ Rewiring chaperone-mediated autophagy in cancer by a prion-like chemical inducer of proximity to counteract adaptive immune resistance(2023)56 cited
→ A Rab5 GTPase module is important for autophagosome closure(2017)53 cited
→ De Novo Nano‐Erythrocyte Structurally Braced by Biomimetic Au(I)‐peptide Skeleton for MDM2/MDMX Predation toward Augmented Pulmonary Adenocarcinoma Immunotherapy(2021)52 cited

→ A general-purpose Nanohybrid fabricated by Polymeric Au(I)-peptide precursor to wake the function of Peptide Therapeutics(2020)

44 cited

→ Turing milk into pro-apoptotic oral nanotherapeutic: De novo bionic chiral-peptide supramolecule for cancer targeted and immunological therapy(2022)38 cited

→ Carnosic acid-induced co-self-assembly of metal-peptide complexes into a nanocluster-based framework with tumor-specific accumulation for augmented immunotherapy(2021)32 cited

→ From foe to friend: Rewiring oncogenic pathways through artificial selenoprotein to combat immune-resistant tumor(2025)32 cited